Evidence map›Paper›PMID 39575624›Full record

Observational studyNuclear medicine communications2025

Predictive value of thyroglobulin after radioiodine therapy for excellent response to treatment in postoperative thyroid cancer.

Yuan Zhu, Xiaoying Yang, Zhao Liu, Qinghua Zhang, Zhiyong Li, Xiancun Hou, Hui Zhu

Abstract readObservational Study
In one paragraph

Observational study in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuan ZhuDepartments of Nuclear Medicine.
Xiaoying YangRadiology, The Affiliated Hospital of Xuzhou medical University, Xuzhou, China.
Zhao LiuDepartments of Nuclear Medicine.
Qinghua ZhangDepartments of Nuclear Medicine.
Zhiyong LiDepartments of Nuclear Medicine.
Xiancun HouDepartments of Nuclear Medicine.
Hui ZhuDepartments of Nuclear Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to assess the usefulness of thyroglobulin (Tg) after radioiodine (RAI) therapy in predicting excellent response (ER) to therapy in postoperative differentiated thyroid cancer (DTC).

methodsA retrospective observational study was conducted on postoperative DTC patients who underwent RAI from August 2018 to December 2022. Various factors were analyzed to predict ER to treatment. This involved Tg under stimulation (sTg) before RAI, Tg immediately (imTg) 112 h post-RAI and imTg/sTg(rTg). Based on the efficacy of RAI, patients were categorized into two groups: ER and non-ER (NER). Univariate logistic analysis was utilized to compare parameters between the two groups, followed by binary logistic regression analysis on factors associated with ER. Receiver operating characteristic (ROC) curves were employed to evaluate the sensitivity, specificity, and optimal diagnostic cutoff points for parameters affecting ER.

resultsThe analysis included 45 ER patients and 56 NER patients. Statistical significance was found in the binary logistic regression analysis for the number of lymph nodes in the lateral cervical region ( P  = 0.016), sTg ( P  = 0.021), and rTg ( P  ≤ 0.001) concerning ER. ROC curve analysis revealed that the rTg area under the curve was 0.845, with an optimal cutoff value of 11.78, sensitivity of 82.6%, and specificity of 74.5%.

conclusionPost-RAI therapy, significant value is demonstrated by rTg with high sensitivity and specificity. This provides a foundation for the evaluation and decisions about DTC treatment in advance.

Indexed as

Iodine RadioisotopesThyroglobulinThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPostoperative PeriodPredictive Value of TestsRetrospective StudiesTreatment OutcomeIodine RadioisotopesThyroglobulin

Identifiers

PMID39575624
PMCPMC11706346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.